Solving the mystery of named resource management in life sciences project management for organizational effectiveness

Why LLM Fine-Tuning is the next competitive advantage for life sciences

Global life sciences companies operate under sustained competitive pressure to accelerate scientific innovation while simultaneously ensuring operational efficiency and cost discipline across all functions. In this environment, Large Language Models (LLMs) are emerging as a transformative acceleration engine, enabling organizations to bypass traditionally sequential and manually intensive steps and achieve task specific outcomes far faster than before. From conducting competitive due diligence to drafting regulatory documents, and from generating novel chemical compounds to supporting clinical evidence, the role of artificial intelligence is becoming increasingly aspirational and is now considered essential for pharmaceutical growth and improved patient outcomes.These models, while highly capable of understanding general pharmaceutical concepts, do not inherently possess the organization specific knowledge, internal reasoning patterns, or established methods for interpreting and presenting scientific information that teams rely on in real workflows. As a result, the limitations of off-the-shelf LLMs create a structural ceiling that prevents wider adoption in areas where organizations depend on highly skilled, specialized, and rate limiting scientific processes. Another major challenge is the need to protect sensitive intellectual assets that pharmaceutical companies would otherwise have to expose to external LLMs providers.LLM fine tuning directly addresses these gaps by adapting the model to an organization’s internal knowledge, scientific conventions, and established decision frameworks. By training the model on proprietary datasets such as experimental records, regulatory submissions, archived study protocols, internal reports, and domain specific terminology, fine tuning enables the LLMs to reason and generate outputs that align with the organization’s real workflows. Fine tuning also improves the model’s ability to interpret scientific evidence, maintain consistent terminology, and follow the organization’s established communication and documentation patterns.Furthermore, when a fine-tuned model is hosted internally through a sovereign deployment approach, data security concerns are mitigated because sensitive information remains within the organization’s-controlled environment. This ensures full protection of intellectual assets while still enabling advanced model performance.This alignment allows the model to replicate expert level writing styles, meet internal quality standards, and understand the detailed structure of scientific evidence, hypotheses, and decisions within the company. As a result, fine-tuned LLMs overcome the ceiling imposed by generic models, enabling artificial intelligence to be deployed securely in highly skilled and rate limiting processes that previously depended exclusively on specialized scientific expertise.In this blog, we explore the essential aspects of model fine tuning and discuss the primary considerations that guide the decision to implement this methodology.The Limits of Generic LLMs in a Regulated and IP‑Sensitive IndustryEvery pharmaceutical organization operates within a highly specialized and tightly governed environment. Internal processes, regulatory documentation styles, scientific interpretation frameworks, and communication protocols are often unique to each company. At the same time, the industry works with highly sensitive intellectual property, proprietary data assets, and confidential patient information that must be managed within strict compliance frameworks.Generic, publicly available language models are powerful, scalable, and highly capable. They already demonstrate exceptional performance in improving operational efficiency and reducing the cost of decision-making across multiple industries. Yet, when applied directly to domain-specific pharmaceutical use cases, they present both constraints and risks. These models may not fully understand scientific terminology in context, internal organizational language, regulatory nuance, or the decision frameworks embedded in pharmaceutical R&D. More critically, they may not always be suitable for use with proprietary or sensitive datasets without robust controls.To address these challenges, organizations often begin with techniques such as Retrieval Augmented Generation (RAG), in-context learning, and structured prompt engineering. While these methods can improve model relevance and mitigate some risks, they do not fully align the model with the organization’s internal language, domain knowledge, and governance expectations.This is where model fine tuning becomes a strategic differentiator.Fine Tuning as the Path to Enterprise Aligned IntelligenceFine tuning is the process of training an open weights language model on curated, domain specific datasets so that it can internalize specialized knowledge, organization specific terminology, and preferred communication structures. In simple terms, it aligns the behavior of the model with the way an enterprise thinks, writes, reasons, and operates. This is the foundation of enterprise LLM fine tuning and a key differentiator in modern LLM implementation strategies.The result is a custom LLM that does not simply answer questions but demonstrates contextual understanding that is relevant to therapeutic areas, research processes, clinical frameworks, and regulatory environments. Essential Building Blocks for Custom LLM DevelopmentTo harness meaningful enterprise value while maintaining compliance, data security, and intellectual property protection, pharmaceutical organizations must adopt a structured and disciplined approach to enterprise LLM fine-tuning. A mature LLM implementation framework should be built on the following foundational elements:1. Selection of the right base modelSelecting the appropriate foundation model is a strategic decision that directly influences scalability, regulatory posture, and long-term model sovereignty. For pharmaceutical R&D and clinical environments, the base model must demonstrate strong baseline reasoning in scientific and medical language, high context handling capability for long technical documents, and architectural flexibility to support parameter-efficient fine-tuning. Beyond raw performance, enterprises must evaluate licensing structures, model transparency, and deployability within secure, on-prem or private cloud environments to ensure full control over intellectual property and patient-sensitive data.Equally critical is assessing the model’s prior training exposure to biomedical and regulatory language patterns. Models with stronger scientific priors typically require less domain adaptation effort, reducing fine-tuning cost and risk. 2. Robust data pipeline reviewIn pharmaceutical organizations, the value of fine-tuning is fundamentally determined by the quality, lineage, and governance of internal data assets. A rigorous data pipeline review must address ingestion across structured (clinical databases, assay data), and unstructured sources (protocols, medical narratives, regulatory correspondence). Data must undergo systematic curation, normalization, de-identification where applicable, and metadata enrichment to ensure both compliance and semantic coherence for model learning.Beyond data engineering, enterprises must implement traceability mechanisms that link training data back to source systems and governance policies. This is essential for audit readiness, bias investigation, and future model revalidation. Attention should be given to versioning of datasets, controlled vocabulary alignment (e.g., MedDRA, CDISC), and separation of training, validation, and post-deployment feedback loops. A robust pipeline ensures that fine-tuning becomes a repeatable enterprise capability rather than a one-off experiment.3. Fine-tuning methodologyNot all pharma use cases warrant the same depth of model modification. The fine-tuning strategy must be explicitly aligned with the maturity of the use case and its potential impact on scientific, clinical, or regulatory outcomes. Early-stage knowledge assistance or literature synthesis may benefit from lightweight approaches such as parameter-efficient fine-tuning or instruction tuning. In contrast, higher-risk applications e.g., protocol optimization support or signal detection augmentation, may require deeper domain adaptation combined with human-in-the-loop controls.4. Comprehensive model performance assessmentModel evaluation must extend across multiple performance dimensions, including factual reliability in scientific contexts, robustness to ambiguous or incomplete inputs, and stability across therapeutic domains. Benchmarking should include domain-specific test sets derived from internal documents, regulatory texts, and real-world operational queries.Bias and safety evaluation is equally critical. Models must be assessed for skewed outputs related to patient demographics, therapeutic areas, or study geographies, particularly in clinical and safety applications.5. Model deployment and governance frameworkDeploying fine-tuned models in pharma requires an enterprise-grade governance framework that integrates security, compliance, and operational oversight. Models must be hosted within secure environments that align with corporate data protection standards, ensuring that proprietary compounds data, clinical records, and regulatory documents remain within organizational boundaries. Role-based access controls, logging, and full interaction traceability are essential to meet audit requirements.Governance must also encompass lifecycle management, this includes model version control, change management procedures, revalidation triggers, and retirement policies. Documentation standards should support inspection readiness and demonstrate that the model behaves consistently within defined performance boundaries. i2e’s Point of viewWe recommend that fine tuning be viewed not as a technical experiment but as a strategic lever to embed institutional knowledge into AI systems and create sustainable competitive advantage. It enables organizations to build AI capabilities that are context aware, aligned with governance expectations, and operationally scalable within a regulated environment.While fine tuning is a powerful enabler, its success depends on clearly defined problem statements, validated business needs, a disciplined data strategy, and strong cross functional collaboration across IT, R and D, Quality, Legal, and Compliance teams.We believe that early adopters will gain a meaningful advantage by learning quickly from both successful implementations and early limitations, allowing them to evolve toward more advanced capabilities and accelerate enterprise readiness. As organizations refine their LLM implementation practices and deepen their fine-tuning expertise, they build the internal capacity required to scale custom models safely and effectively across functions.Looking ahead, the workforce will increasingly depend on such models as core tools for scientific, operational, and regulatory work. Organizations that invest early in fine-tuned models will not only strengthen business continuity but also create a modern digital environment that attracts and retains high quality talent who expect AI enabled workflows as part of their daily roles.

Microsoft Project Online is retiring: What’s next for organizations?

Microsoft Project Online RetirementMicrosoft has officially announced the retirement of Project Online, marking a major shift in how organizations manage projects and portfolios in the Microsoft ecosystem. While this move may seem disruptive, it’s also an opportunity to modernize your project management landscape with more agile, connected, and scalable solutions.What is retiring and what is not within the MS Project Management ecosystem CategoryProduct / Component StatusProject OnlineMicrosoft Project Online (part of Project for Web and Project Online Plans 1–5) Retiring (officially retiring on September 30, 2026)Project ServerProject Server Subscription Edition (on-premises)Not retiring (Microsoft has committed to supporting it through at least July 14, 2031)Project Server 2019 / 2016 / 2013Legacy on-prem versionsRetiring / Out of mainstream supportPlanner PremiumMicrosoft Planner (and Planner Premium)Active / ExpandingProject Desktop ClientMicrosoft Project Professional (Desktop app)Still available but staticWhat should be your next steps?Our PPM experts identified four key paths forward, some cover Microsoft project alternatives within the Microsoft ecosystems, where are some options go outside Microsoft. Here is a detailed look at their pros, cons, and technical implications to help you make an informed choice. 1. Move to Microsoft Planner with premium capabilities / Power Platform extensionsMicrosoft Planner has evolved beyond a simple task board. With Planner Premium (built on Microsoft Project for the web) and Power Platform integration, organizations can create scalable, low-code project management environments that automate workflows, connect to data sources, and deliver analytics. They can easily recreate their MS Project plans within Planner Premium or extend them using Power Platform components for automation and reporting.Pros:Modern UI and simplicity: Intuitive, cloud-native experience with integration into Teams and Microsoft 365.Automation and customization: Power Automate, Power Apps, and Dataverse enable custom workflows and reporting.Scalable and future-ready: Microsoft’s strategic focus is clearly on the Power Platform–Planner stack, ensuring continued innovation.Unified data model: Leverages Dataverse for consistent data handling and analytics via Power BI.Cons:Migration complexity: Data structures in Project Online differ from Planner/Dataverse, requiring careful mapping and reconfiguration.Feature gaps: Advanced portfolio-level functions (like EVM or multi-dimensional resource planning) require custom builds or add-ons.Change management effort: End users need to adapt to new workflows and interfaces.Cost implications:Low to moderate initial cost: Most Planner Premium and Power Platform capabilities come under existing Microsoft 365 or Power Platform licenses.Implementation costs vary: Custom app development, workflow setup, and Power BI dashboarding can add moderate consulting expenses.Ongoing savings: Reduced infrastructure costs and seamless integration minimize total cost of ownership (TCO). 2. Move to Project Server Subscription Edition (On-Premises)For organizations not ready to go fully cloud-native, Microsoft Project Professional and Project Server Subscription Edition offers a supported, on-premises continuation of Project Online capabilities.Pros:Continuity with existing processes: Familiar interface, enterprise resource planning, and enterprise custom fields, and project detail pages remain intact.Control and compliance: Data stays on-premise—ideal for regulated industries with strict data residency requirements.Integration consistency: Existing add-ins, reports, and integrations can often be retained with minimal rework.Cons:Limited innovation: Microsoft’s development focus has shifted to the cloud; few routine updates are expected.Higher maintenance overhead: Infrastructure, patching, and scalability remain your responsibility.Scalability constraints: Not ideal for distributed or hybrid teams needing mobile/cloud access.Cost implications:High capital cost: Requires on-prem servers, SQL licensing, and ongoing hardware maintenance.Lower migration cost: Minimal configuration changes compared to cloud migration.Higher long-term cost: IT resource overhead, patching, and version upgrades add recurring expenses. 3. Hybrid or mixed approachMany enterprises choose a hybrid setup, using Planner and Power Platform for agile, team-level project tracking while retaining Project Server for enterprise-level program management.Pros:Balanced modernization: Gradual migration minimizes disruption.Best of both worlds: Agile teams get flexibility while PMOs retain robust governance tools.Phased adoption: Allows time to retrain teams and adjust processes.Cons:Integration complexity: Requires connectors or middleware to keep systems in sync.Dual administration: Managing both environments increases oversight effort.Data consistency risks: Without clear governance, data integrity may be affected.Cost implications:Moderate setup cost: Investment in integration tools and Power Platform customization.Reduced upfront burden: Avoids full migration costs by spreading transformation over phases.Higher operational cost: Running and maintaining two environments can increase ongoing spend. 4. Switch to third-party enterprise PPM toolsFor organizations looking for end-to-end project and portfolio management with built-in financials, resource planning, and risk management, third-party tools like Planisware, Clarity, Smartsheet, Monday.com, Planview, OnePlan or Wrike offer comprehensive alternatives.Pros:Rich PPM functionality: Mature features for scenario planning, capacity management, and financial tracking.Industry-specific capabilities: Tailored solutions for pharma, engineering, or R&D.Dedicated vendor innovation: Regular updates and roadmap-driven enhancements.Embedded AI support: Built-in AI agents to streamline everyday project management activities and decision-making.Cons:High licensing cost: Enterprise-level subscriptions can be significant.Complex migration: Requires data mapping, validation, and process reengineering.Reduced Microsoft integration: Some features may require additional connectors or third-party middleware.Cost implications:High upfront investment: Licensing, implementation, and integration costs can be substantial.Predictable recurring costs: Annual subscriptions and vendor-managed support simplify budgeting.Potential savings in efficiency: Rich automation and portfolio analytics can deliver ROI over time. Make the right choice with i2eAt i2e, we help organizations evaluate their Project Online footprint, assess migration complexity, and select the right modernization path—balancing functionality, cost, and long-term strategy. Check out our 7 steps migration roadmap.Our consultants specialize in Microsoft PPM modernization, Power Platform automation, and data integration, ensuring a smooth transition with minimal downtime. Whether your goal is cost optimization, enhanced agility, or future scalability, we design a roadmap that aligns with your business priorities.Frequently Asked Questions .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. When is Microsoft Project Online retiring? Microsoft has announced that Microsoft Project Online will officially retire on September 30, 2026. After this date, the service will no longer be available and organizations will lose access to their projects and associated data unless they migrate beforehand. 2. What happens to project data after Microsoft Project Online is retired? Once Project Online is retired, all projects, schedules, and data stored in the platform will become inaccessible. Organizations must export or migrate their data to another system before the retirement date to maintain access. 3. Is the Project Online retirement an opportunity to modernize project management? Yes. Many organizations are using the retirement as an opportunity to modernize project portfolio management, improve reporting, and integrate project planning more closely with tools like Microsoft Teams, Power Platform, and modern PPM platforms. 4. What are the alternatives to Microsoft Project Online? Organizations can consider alternatives such as Microsoft Planner, Microsoft Project Server, or modern project portfolio management (PPM) platforms depending on their needs.

6 Warning signs your PPM tool is holding you back and how to fix them?

6 Warning signs your PPM tool is holding you back and how to fix them? In a market flooded with Project Portfolio Management (PPM) tools, it is important to find one tool or a combination that fits your business needs, but does it end there? No, it doesn't. As portfolios continue to grow and evolve, so should the tools and processes around them.Right from the evaluation of PPM tool capabilities and integration potential, to ensuring alignment with your project workflows, team structures, and governance models, the journey is anything but straightforward. What looks good on paper may fall short in practice if the tool doesn’t support your organization’s decision-making rhythms, reporting needs, or future scalability. In this blog, we unpack some of the signs that indicate your current PPM may not be working for you.6 Signs to change or upgrade your PPM toolWhether you are managing a local functional level portfolio, or a global multi-therapy portfolio, your PPM tool should scale to match your future vision. Most of the times, the real problem lies in improper customization of the tool, or lack of proper alignment of the tool with the processes around it.As time passes, even the most robust tools can quietly become misaligned as your portfolio grows in complexity and your processes and tool cannot catch up.Here are 6 signs to watch out when your portfolio is growing.1. Lack of visibility and transparencyIn life sciences, where development timelines span years, costs reach billions, and go/no-go decisions hinge on granular data, lack of visibility isn’t just inconvenient—it’s risky. If stakeholders struggle to see the true status of projects, resource bottlenecks, or shifting priorities across the portfolio, it’s often because the PPM tool isn’t surfacing the right information in the right format.This can result inLack of progress visibility to the clinical project leadsResource managers cannot access real-time insights over-allocations across cross-functional teams.Finance and strategy teams operating with inconsistent dataLimited visibility to the senior leadership for proactive decision-makingThe fix: Integrate data across functions and systemsEnable role-based dashboardsConnect strategic governance to operational executionAdopt a layered approach: tools+analytics+services2. Relying on manual processesIf your team is still exporting data from the PPM tool to create trackers, forecasts, or summaries in excel, they are building parallel processes outside the system. In life sciences, clinical milestones are tied to regulatory submissions, resource planning needs to be done across multiple functional roles, and cost forecasting should be incorporated into scenario planning and PTRS-based risk adjustments. When spreadsheets are used for any of the above, it breaks traceability, auditability, and data integrity—which are non-negotiables in pharma.The fix:Audit what is being done outside the tool and whyMap critical decision areas (e.g., resource trade-offs, milestone projections, risk-adjusted value)Extend your current PPM tool with tailored integrations3. Difficulty adapting to strategic changeIn life sciences, strategic agility isn’t optional—it’s mission-critical.Pipeline reprioritizations, licensing deals, market shifts, regulatory delays, and clinical data surprises are part of daily life. When your PPM tool can’t adapt quickly to these realities, it doesn’t just slow down operations—it weakens your strategic posture.If your current tool requiresManual rework to update forecasts or resource allocationsWeeks to reflect new prioritizations from governanceOffline modeling of portfolio impactsThese can cause serious issues during some strategic triggers that require rapid adaptation. For example, businesses acquiring a biotech pipeline- Entire new projects and data sets need to be integrated rapidly.The fix:Enable scenario modeling within the PPM environmentTie prioritization to strategic driversAllow real-time, role-based replanningConnect strategic decisions to execute workflows4. Data silos and integration issuesWhen systems cannot talk, people build manual work arounds, and that’s when errors, delays, and mismatches happen.In life sciences, portfolio success depends on how accurate and real-time the data is flowing between clinical, regulatory, finance, and commercial teams. But if your PPM tool is not integrated well, it creates data silos, and decision-making blind spots.For example,Clinical trial milestones are updated in the CTMS but not reflected in portfolio timelines, Finance forecasts in SAP does not align with resource assumptions in the PPM tool,Resource planning tools operate separately from program plans, creating over- or under-utilizationThe result? Reporting becomes reactive, portfolio insights become outdated, and governance decisions are made on partial or inconsistent data.The fix:Identify and map critical data touchpointsUse APIs , data warehouses, or middleware for seamless flowCentralize reporting with a unified data layerImprove adoption by reducing complexity5. Frequent project delays and missed timelinesIn life sciences, R&D timelines stretch over years, and project delays and missed timelines can impact patient access, revenue realization, and consistent project overruns. If projects across your portfolio areSlipping their milestonesMissing regulatory submissions targetsRequiring last-minute firefighting on resource or budget allocationAnd the project teams have no visibility before this can happen, so it’s often not the science or the team—it’s a sign that the PPM tool is no longer providing the right foresight to plan and execute effectively.The fix:Configure timeline logic to reflect real-world dependenciesAdd risk triggers and milestone health checks inside the toolEmbed resource forecasting modules into the toolActivate portfolio-level impact tracking6. Lack of reporting and analyticsIf your PPM tool cannot generate the right reports, or it is bound to export raw data to just build custom views, then your PPM tool is slowing down decision making or is causing the team to rely on outdated decisions.Common indicators areComplicated to compare budget vs actuals by function or programReports lacking granularity and clarityStatic portfolio views with no trend lines, variance tracking and drilldownsWithout timely, trusted insights, your team is stuck in reactive mode—reporting the past instead of steering the future. It is time to explore the reporting capabilities of your existing tool or evaluate the need to build an external reporting system.The fixDesign role-based dashboards for decision-makersIntegrate real-time performance tracingInclude trend analysis and historical viewsLayer predictive analytics for decisionsBuild Reporting Database and integrate data from PPM tool, financial toolsConclusionAdopting a PPM tool means countless hours of research, training and change management. Even if you notice one or many of these warning signs, you need not always replace the entire tool. Many times, with a few customizations and process fixes, portfolio management systems can be configured to support your growing portfolio needs.i2e can helped global life sciences organizations fix and extend their PPM tool capabilities byDesigning a maturity-based roadmap customized to your portfolio complexityExtending the current PPM tool with integrated analytics and dashboardsConfiguring milestone logic, risk signals, and resource forecasting inside your toolAutomating reporting and scenario planning across portfolio layers Frequently Asked Questions .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. How do I know if my current PPM tool is no longer meeting my business needs? If your PPM tool lacks real-time visibility, relies on spreadsheets, has poor integrations, or cannot adapt to strategic changes, it may no longer support effective project portfolio management and should be upgraded or extended. 2. Why is Project Management for Pharmaceutical Industry more complex than other industries? Pharma projects are complex due to long timelines, strict regulations, high costs, and cross-functional dependencies, requiring robust tool for effective management. 3. Why is cross-functional visibility important in Project Management for Pharmaceutical Industry? Real-time visibility ensures clinical, regulatory, finance, and commercial teams can make informed decisions, avoid bottlenecks, and manage risks across the portfolio in Project and Portfolio Management.